Katie Lapidus

Associate
Full contact info

Passions

True Crime

Peloton

Experience

Alto Neuroscience Announces $147.9 Million IPO

February 6, 2024

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Christina T. Roupas
Partner in Charge – Chicago, Chicago
Courtney M.W. Tygesson
Partner, Chicago
Laurie Bauer
Partner, Chicago
Nyron J. Persaud
Partner, New York
Kate Hillier
Partner, Seattle
Jon Cousin
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Geoffrey Spolyar
Partner, Boston
Stephanie Gentile
Partner, New York
Steve Flores
Partner, Chicago
Peter Adams
Partner, San Diego
Phil Mitchell
Partner, New York
Courtney Thorne
Partner, Boston
David Navetta
Partner, Colorado
Francis Wheeler
Partner, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Rebecca Ross
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Dani Nazemian
Special Counsel, San Diego
Katie Lapidus
Associate, Washington, DC
Trey Reilly
Associate, New York
Adam Bloom
Associate, Chicago
David D. Suh
Associate, Palo Alto
Dionne A. Thomas
Associate, San Diego
Megan E. Bowles
Associate, Chicago
Mor Agam
Associate, New York
Nat Sherrick
Associate, Washington, DC
Edmond Lay
Associate, San Diego
Addison Pierce
Associate, Chicago
Calvin Lee
Associate, New York
Andrew Nelms
Associate, San Francisco
Jason Minio
Paralegal Specialist, Boston
Jeffery Wyzykowski
Patent Agent, Washington, DC

Related Practices & Industries

Cara Therapeutics, Inc. -- $40 Million Royalty Interest Purchase and Sale Agreement

November 3, 2023

Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.

Related contacts

Michael Tollini
Partner, Washington, DC
Addison Pierce
Associate, Chicago
Bin Wang
Special Counsel, Palo Alto
Xueqing Li
Associate, San Francisco
Jordan Verrilli
Associate, New York
Mor Agam
Associate, New York
Katherine Denby
Associate, Washington, DC
Darren DeStefano
Partner, Reston
Katie Lapidus
Associate, Washington, DC
Steve Flores
Partner, Chicago
Xander Lee
Partner, Los Angeles Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Francis Wheeler
Partner, Colorado

Related Practices & Industries

Immunology Company argenx Announces $1.27 Billion Global Offering

July 26, 2023

Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.

Read more

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Darah Protas
Partner, Washington, DC
Charles York
Associate, New York
Katie Lapidus
Associate, Washington, DC
Carley Cruea
Associate, Washington, DC
Bill Christiansen
Partner, Seattle
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Dr. Tian Yong Zheng
Patent Agent, Seattle

Related Practices & Industries

NewAmsterdam Pharma – $181.6 Million Follow-on Offering

June 6, 2023

Cooley advised the underwriters in NewAmsterdam Pharma’s $181.6 million follow-on offering. NewAmsterdam is a clinical-stage biopharmaceutical company with a mission to improve care of patients with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. Lawyers Eric Blanchard, Div Gupta, Jean Park, Minkyu Park, Charles York, and Katie Lapidus led the Cooley team.

Related contacts

Eric Blanchard
Partner, Boston
Div Gupta
Partner, New York
Jean Park
Partner, New York
Minkyu Park
Associate, New York
Charles York
Associate, New York
Katie Lapidus
Associate, Washington, DC

Related Practices & Industries

Prelude Therapeutics – $100 Million Follow-on Offering

May 18, 2023

Cooley advised the underwriters in Prelude Therapeutics’ $100 million follow-on offering. Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Lawyers Richard Segal, Div Gupta, Darah Protas, Sam Paullin and Katie Lapidus led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Virat Gupta
Associate, Washington, DC
Darah Protas
Partner, Washington, DC
Samuel Paullin
Associate, Chicago
Katie Lapidus
Associate, Washington, DC

Related Practices & Industries

View more

Admissions and credentials

District of Columbia